Article Commentary: The Management of the Trauma Patient with Medically-Altered Coagulation

Abstract

Get full access to this article

View all access options for this article.

References

Perdue

P.W.

, Watts

D.D.

, Kaufmann

C.R.

, Trask

A.L.

Differences in mortality between elderly and younger adult trauma patients: Geriatric status increases risk of delayed death.

J Trauma 1998; 45: 805–10.

Broos

P.L.

, D'Hoore

, Vanderschot

Multiple trauma in elderly patients. Factors influencing outcome: Importance of aggressive care.

Injury 1993; 24: 365–8.

Champion

H.R.

, Copes

W.S.

, Buyer

Major trauma in geriatric patients.

Am J Public Health 1989; 79: 1278–82.

Bick

R.L.

, Murano

Physiology of hemostasis.

Clin Lab Med 1994; 14: 677–707.

Gaffney

P.J.

, Edgell

T.A.

, Whitton

C.M.

The haemostatic balance—Astrup revisited.

Haemostasis 1999; 29: 58–71.

Bombeli

, Mueller

, Haeberli

Anticoagulant properties of the vascular endothelium.

Thromb Haemost 1997; 77: 408–23.

de Gaetano

Historical overview of the role of platelets in hemostasis and thrombosis.

Haematologica 2001; 86: 349–56.

Packham

M.A.

Role of platelets in thrombosis and hemostasis.

Can J Physiol Pharmacol 1994; 72: 278–84.

Cotran

R.S.

, Kumar

, Collins

, Robbins

S.L.

Robbins Pathologic Basis of Disease, 6th Ed. Philadelphia: WB Saunders, 1999.

10.

Harker

L.A.

, Hanson

S.R.

, Kelly

A.B.

Antithrombotic strategies targeting thrombin activities, thrombin receptors and thrombin generation.

Thromb Haemost 1997; 78: 736–41.

11.

Pearson

T.A.

, LaCava

, Weil

H.F.

Epidemiology of thrombotic-hemostatic factors and their associations with cardiovascular disease.

Am J Clin Nutr 1997; 65(5 Suppl): 1674S–82S.

12.

Rosendaal

F.R.

Venous thrombosis: Prevalence and interaction of risk factors.

Haemostasis 1999; 29 Suppl S1: 1–9.

13.

Burch

J.W.

, Stanford

, Majerus

P.W.

Inhibition of platelet prostaglandin synthetase by oral aspirin.

J Clin Invest 1978; 61: 314–9.

14.

Kocsis

J.J.

, Hernandovich

, Silver

M.J.

Duration of inhibition of platelet prostaglandin formation and aggregation by ingested aspirin or indomethacin.

Prostaglandins 1973; 3: 141–4.

15.

Patrono

Aspirin as an antiplatelet drug.

N Engl J Med 1994; 330: 1287–94.

16.

Cyrus

, Yao

, Tung

L.X.

, Pratico

Stabilization of advanced atherosclerosis in low-density lipoprotein receptor-deficient mice by aspirin.

Atherosclerosis 2006; 184: 8–14.

17.

O'Brien

J.R.

Effects of salicylates on human platelets.

Lancet 1968; 1: 779–83.

18.

Final report on the aspirin component of the ongoing Physicians’ Health Study.

Steering Committee of the Physicians’ Health Study Research Group.

N Engl J Med 1989; 321: 129–35.

19.

Thrombosis prevention trial: Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk.

The Medical Research Council's General Practice Research Framework.

Lancet 1998; 351: 233–41.

20.

Peto

, Gray

, Collins

Randomised trial of prophylactic daily aspirin in British male doctors.

Br Med J (Clin Res Ed) 1988; 296: 313–6.

21.

Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.

Antiplatelet Trialists’ Collaboration.

BMJ 1994; 308: 81–106.

22.

Tran

, Anand

S.S.

Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.

JAMA 2004; 292: 1867–74.

23.

Dorffler-Melly

, Koopman

M.M.

, Adam

D.J.

Antiplatelet agents for preventing thrombosis after peripheral arterial bypass surgery.

Cochrane Database Syst Rev 2003(3): CD000535.

24.

Moore

W.S.

, Barnett

H.J.

, Beebe

H.G.

Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the Ad Hoc Committee, American Heart Association.

Circulation 1995; 91: 566–79.

25.

Aronow

W.S.

Management of peripheral arterial disease.

Cardiol Rev 2005; 13: 61–8.

26.

Gachet

, Cazenave

J.P.

, Ohlmann

ADP receptor-induced activation of guanine-nucleotide-binding proteins in human platelet membranes.

Eur J Biochem 1992; 207: 259–63.

27.

Gachet

, Stierle

, Cazenave

J.P.

The thienopyridine PCR 4099 selectively inhibits ADP-induced platelet aggregation and fibrinogen binding without modifying the membrane glycoprotein IIb-IIIa complex in rat and in man.

Biochem Pharmacol 1990; 40: 229–38.

28.

D'Sa

, Machin

S.J.

Clopidogrel: A novel antiplatelet agent.

Hosp Med 1999; 60: 362–3.

29.

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

CAPRIE Steering Committee.

Lancet 1996; 348: 1329–39.

30.

Harker

L.A.

, Boissel

J.P.

, Pilgrim

A.J.

, Gent

Comparative safety and tolerability of clopidogrel and aspirin: Results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events.

Drug Saf 1999; 21: 325–35.

31.

Jneid

, Bhatt

D.L.

, Corti

Aspirin and clopidogrel in acute coronary syndromes: Therapeutic insights from the CURE study.

Arch Intern Med 2003; 163: 1145–53.

32.

Mehta

S.R.

, Yusuf

Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention.

J Am Coll Cardiol 2003; 41(Suppl S): 79S–88S.

33.

Mehta

S.R.

Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI-CURE.

J Invasive Cardiol 2003; 15 Suppl B: 17B–20B; discussion 20B-21B.

34.

Waksman

, Ajani

A.E.

, Pinnow

Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS.

Circulation 2002; 106: 776–8.

35.

Waksman

, Ajani

A.E.

, White

R.L.

Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS).

Circulation 2001; 103: 2332–5.

36.

Heeg

B.M.

, Peters

R.J.

, Botteman

, van Hout

B.A.

Longterm clopidogrel therapy in patients receiving percutaneous coronary intervention.

Pharmacoeconomics 2007; 25: 769–82.

37.

Tricoci

, Roe

M.T.

, Mulgund

Clopidogrel to treat patients with non–ST-segment elevation acute coronary syndromes after hospital discharge.

Arch Intern Med 2006; 166: 806–11.

38.

Zambahari

, Kwok

O.H.

, Javier

Clinical use of clopidogrel in acute coronary syndrome.

Int J Clin Pract 2007; 61: 473–81.

39.

Hirsh

Mechanism of action and monitoring of anticoagulants.

Semin Thromb Hemost 1986; 12: 1–11.

40.

Hirsh

, Dalen

J.E.

, Deykin

, Poller

Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range.

Chest 1992; 102(4 Suppl): 312S–26S.

41.

Haas

Recommendations for prophylaxis of venous thromboembolism: International Consensus and the American College of Chest Physicians Fifth Consensus Conference on anti-thrombotic therapy.

Curr Opin Pulm Med 2000; 6: 314–20.

42.

du Breuil

A.L.

, Umland

E.M.

Outpatient management of anticoagulation therapy.

Am Fam Physician 2007; 75: 1031–42.

43.

Nutescu

E.A.

Assessing, preventing, and treating venous thromboembolism: Evidence-based approaches.

Am J Health Syst Pharm 2007; 64(Suppl 7): S5–13.

44.

Prandoni

, Noventa

, Ghirarduzzi

The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.

Haematologica 2007; 92: 199–205.

45.

Renzulli

, Vitale

, Caruso

Thrombolysis for prosthetic valve thrombosis: indications and results.

J Heart Valve Dis 1997; 6: 212–8.

46.

Li-Saw-Hee

F.L.

, Lip

G.Y.

Atrial fibrillation, thromboembolism and antithrombotic therapy.

Int J Clin Pract 1999; 53: 110–7.

47.

Morley

, Marinchak

, Rials

S.J.

, Kowey

Atrial fibrillation, anticoagulation, and stroke.

Am J Cardiol 1996; 77: 38A–44A.

48.

Hurlen

, Abdelnoor

, Smith

Warfarin, aspirin, or both after myocardial infarction.

N Engl J Med 2002; 347: 969–74.

49.

Greenlund

K.J.

, Zheng

Z.J.

, Keenan

N.L.

Trends in self-reported multiple cardiovascular disease risk factors among adults in the United States, 1991–1999.

Arch Intern Med 2004; 164: 181–8.

50.

Kramarow

, Lubitz

, Lentzner

, Gorina

Trends in the health of older Americans, 1970–2005.

Health Aff (Millwood) 2007; 26: 1417–25.

51.

Increases in age-group–specific injury mortality—United States, 1999–2004.

MMWR Morb Mortal Wkly Rep 2007; 56: 1281–4.

52.

Kauvar

D.S.

, Lefering

, Wade

C.E.

Impact of hemorrhage on trauma outcome: An overview of epidemiology, clinical presentations, and therapeutic considerations.

J Trauma 2006; 60(6 Suppl): S3–11.

53.

Heckbert

S.R.

, Vedder

N.B.

, Hoffman

Outcome after hemorrhagic shock in trauma patients.

J Trauma 1998; 45: 545–9.

54.

Lapointe

L.A.

, Von Rueden

K.T.

Coagulopathies in trauma patients.

AACN Clin Issues 2002; 13: 192–203.

55.

Brohi

, Cohen

M.J.

, Davenport

R.A.

Acute coagulopathy of trauma: Mechanism, identification and effect.

Curr Opin Crit Care 2007; 13: 680–5.

56.

Bickell

W.H.

, Wall

M.J.

Jr. , Pepe

P.E.

Immediate versus delayed fluid resuscitation for hypotensive patients with penetrating torso injuries.

N Engl J Med 1994; 331: 1105–9.

57.

Dutton

R.P.

, Mackenzie

C.F.

, Scalea

T.M.

Hypotensive resuscitation during active hemorrhage: Impact on in-hospital mortality.

J Trauma 2002; 52: 1141–6.

58.

Wade

C.E.

, Kramer

G.C.

, Grady

J.J.

Efficacy of hypertonic 7.5% saline and 6% dextran-70 in treating trauma: A metaanalysis of controlled clinical studies.

Surgery 1997; 122: 609–16.

59.

Finfer

, Bellomo

, Boyce

A comparison of albumin and saline for fluid resuscitation in the intensive care unit.

N Engl J Med 2004; 350: 2247–56.

60.

Holcomb

J.B.

Damage control resuscitation.

J Trauma 2007; 62(6 Suppl): S36–7.

61.

Rotondo

M.F.

, Schwab

C.W.

, McGonigal

M.D.

‘Damage control’: An approach for improved survival in exsanguinating penetrating abdominal injury.

J Trauma 1993; 35: 375–82.

62.

Bochicchio

Treatment of bleeding in the urban battlefield.

Surgery 2007; 142(4 Suppl): S78–83.

63.

Gonzalez

E.A.

, Moore

F.A.

, Holcomb

J.B.

Fresh frozen plasma should be given earlier to patients requiring massive transfusion.

J Trauma 2007; 62: 112–9.

64.

Aguilar

M.I.

, Hart

R.G.

, Kase

C.S.

Treatment of warfarin-associated intracerebral hemorrhage: Literature review and expert opinion.

Mayo Clin Proc 2007; 82: 82–92.

65.

Dutton

R.P.

, McCunn

, Hyder

Factor VIIa for correction of traumatic coagulopathy.

J Trauma 2004; 57: 709–18.

66.

Geeraedts

L.M.

Jr. , Kamphuisen

P.W.

, Kaasjager

H.A.

The role of recombinant factor VIIa in the treatment of life-threatening haemorrhage in blunt trauma.

Injury 2005; 36: 495–500.

67.

Mohr

A.M.

, Holcomb

J.B.

, Dutton

R.P.

, Duranteau

Recombinant activated factor VIIa and hemostasis in critical care: A focus on trauma.

Crit Care 2005; 9(Suppl 5): S37–42.

68.

Stein

D.M.

, Dutton

R.P.

, O'Connor

Determinants of futility of administration of recombinant factor VIIa in trauma.

J Trauma 2005; 59: 609–15.

69.

Cartmill

, Dolan

, Byrne

J.L.

, Byrne

P.O.

Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies.

Br J Neurosurg 2000; 14: 458–61.

70.

Drews

R.E.

Critical issues in hematology: Anemia, thrombocytopenia, coagulopathy, and blood product transfusions in critically ill patients.

Clin Chest Med 2003; 24: 607–22.

71.

Huttner

H.B.

, Schellinger

P.D.

, Hartmann

Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: Comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates.

Stroke 2006; 37: 1465–70.

72.

Makris

, Greaves

, Phillips

W.S.

Emergency oral anticoagulant reversal: The relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy.

Thromb Haemost 1997; 77: 477–80.

73.

Levy

J.H.

, Tanaka

K.A.

The anticoagulated patient: Strategies for effective blood loss management.

Surgery 2007; 142(4 Suppl): S71–7.

74.

Zimmerman

M.A.

, Albright

T.N.

, Raeburn

C.D.

, Selzman

C.H.

Vasopressin in cardiovascular patients: Therapeutic implications.

Expert Opin Pharmacother 2002; 3: 505–12.

75.

Altman

, Scazziota

, de Lourdes Herrera

, Gonzalez

Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation.

J Thromb Haemost 2006; 4: 2022–7.

76.

Thompson

H.J.

, McCormick

W.C.

, Kagan

S.H.

Traumatic brain injury in older adults: Epidemiology, outcomes, and future implications.

J Am Geriatr Soc 2006; 54: 1590–5.

77.

Franko

, Kish

K.J.

, O'Connell

B.G.

Advanced age and preinjury warfarin anticoagulation increase the risk of mortality after head trauma.

J Trauma 2006; 61: 107–10.

78.

Lavoie

, Ratte

, Clas

Preinjury warfarin use among elderly patients with closed head injuries in a trauma center.

J Trauma 2004; 56: 802–7.

79.

Ohm

, Mina

, Howells

Effects of antiplatelet agents on outcomes for elderly patients with traumatic intracranial hemorrhage.

J Trauma 2005; 58: 518–22.

80.

Jones

, Sharp

, Mangram

A.J.

, Dunn

E.L.

The effects of preinjury clopidogrel use on older trauma patients with head injuries.

Am J Surg 2006; 192: 743–5.

81.

Parris

, Hassan

Towards evidence based emergency medicine: Best BETs from the Manchester Royal Infirmary. Does clopidogrel increase morbidity and mortality after minor head injury.

Emerg Med J 2007; 24: 435–6.

82.

Ivascu

F.A.

, Howells

G.A.

, Junn

F.S.

Rapid warfarin reversal in anticoagulated patients with traumatic intracranial hemorrhage reduces hemorrhage progression and mortality.

J Trauma 2005; 59: 1131–7.

83.

Ochsner

M.G.

Factors of failure for nonoperative management of blunt liver and splenic injuries.

World J Surg 2001; 25: 1393–6.

84.

Godley

C.D.

, Warren

R.L.

, Sheridan

R.L.

, McCabe

C.J.

Non-operative management of blunt splenic injury in adults: Age over 55 years as a powerful indicator for failure.

J Am Coll Surg 1996; 183: 133–9.

85.

Croce

M.A.

, Fabian

T.C.

, Menke

P.G.

Nonoperative management of blunt hepatic trauma is the treatment of choice for hemodynamically stable patients. Results of a prospective trial.

Ann Surg 1995; 221: 744–53.

86.

Knudson

M.M.

, Maull

K.I.

Nonoperative management of solid organ injuries. Past, present, and future.

Surg Clin North Am 1999; 79: 1357–71.

87.

Malhotra

A.K.

, Fabian

T.C.

, Croce

M.A.

Blunt hepatic injury: A paradigm shift from operative to nonoperative management in the 1990s.

Ann Surg 2000; 231: 804–13.

88.

Patton

J.H.

Jr. , Croce

M.A.

, Fabian

T.C.

Blunt hepatic trauma: Trends in nonoperative management.

J Tenn Med Assoc 1995; 88: 101–2.

89.

Velanovich

Blunt splenic injury in adults: A decision analysis comparing options for treatment.

Eur J Surg 1995; 161: 463–70.

90.

Babikian

V.L.

, Kase

C.S.

, Pessin

M.S.

Resumption of anticoagulation after intracranial bleeding in patients with prosthetic heart valves.

Stroke 1988; 19: 407–8.

91.

Kawamata

, Takeshita

, Kubo

Management of intracranial hemorrhage associated with anticoagulant therapy.

Surg Neurol 1995; 44: 438–42.

92.

Phan

T.G.

, Koh

, Wijdicks

E.F.

Safety of discontinuation of anticoagulation in patients with intracranial hemorrhage at high thromboembolic risk.

Arch Neurol 2000; 57: 1710–3.